1. Home
  2. PAVM
  3. PAVM News

Latest PAVmed Inc. (PAVM) News on March 24, 2025

Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
PAVM

PR Newswire

11 hours ago

Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening
PAVM

PR Newswire

4 days ago

Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening

Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
PAVM

PR Newswire

6 days ago

Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test
PAVM

PR Newswire

11 days ago

Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test

PAVmed to Hold a Business Update Conference Call and Webcast on March 25, 2025
PAVM

PR Newswire

13 days ago

PAVmed to Hold a Business Update Conference Call and Webcast on March 25, 2025

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025
PAVM

PR Newswire

14 days ago

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025

Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering
PAVM

PR Newswire

19 days ago

Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering

PAVM

MT Newswires

20 days ago

Lucid Diagnostics Prices $15.3 Million Direct Offering

Lucid Diagnostics Announces $15.3 Million Registered Direct Offering
PAVM

PR Newswire

20 days ago

Lucid Diagnostics Announces $15.3 Million Registered Direct Offering

Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard® in At-Risk Patients without Symptomatic GERD
PAVM

PR Newswire

25 days ago

Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard® in At-Risk Patients without Symptomatic GERD

Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement
PAVM

PR Newswire

a month ago

Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement

PAVmed and Subsidiary Veris Health Complete Private Placement Financing
PAVM

PR Newswire

a month ago

PAVmed and Subsidiary Veris Health Complete Private Placement Financing

Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health
PAVM

PR Newswire

a month ago

Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health

PAVM

MT Newswires

a month ago

PAVmed Regains Compliance With Nasdaq Listing Standards

PAVmed Regains Compliance with Nasdaq Stockholders' Equity Requirement
PAVM

PR Newswire

a month ago

PAVmed Regains Compliance with Nasdaq Stockholders' Equity Requirement

Lucid Diagnostics to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
PAVM

PR Newswire

2 months ago

Lucid Diagnostics to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume
PAVM

PR Newswire

2 months ago

Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume

Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
PAVM

PR Newswire

3 months ago

Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters
PAVM

PR Newswire

3 months ago

Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters

Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication
PAVM

PR Newswire

3 months ago

Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication

Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones
PAVM

PR Newswire

4 months ago

Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones

Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test
PAVM

PR Newswire

4 months ago

Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test

Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
PAVM

PR Newswire

4 months ago

Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

PAVmed Third Quarter 2024 Earnings: Misses Expectations
PAVM

Simply Wall St.

4 months ago

PAVmed Third Quarter 2024 Earnings: Misses Expectations

PAVM

Thomson Reuters StreetEvents

4 months ago

Q3 2024 PAVmed Inc Earnings Call

PAVmed Inc (PAVM) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Restructuring
PAVM

GuruFocus.com

4 months ago

PAVmed Inc (PAVM) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Restructuring

PAVmed Provides Business Update and Third Quarter 2024 Financial Results
PAVM

PR Newswire

4 months ago

PAVmed Provides Business Update and Third Quarter 2024 Financial Results

Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
PAVM

PR Newswire

5 months ago

Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers
PAVM

PR Newswire

5 months ago

Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers

PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024
PAVM

PR Newswire

5 months ago

PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024
PAVM

PR Newswire

5 months ago

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024

Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test
PAVM

PR Newswire

5 months ago

Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test

PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care
PAVM

PR Newswire

5 months ago

PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care

Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit
PAVM

PR Newswire

6 months ago

Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit

Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024
PAVM

PR Newswire

6 months ago

Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024

Lucid Diagnostics Holds Inaugural #CheckYourFoodTube Precancer Testing Event for Former NFL Players
PAVM

PR Newswire

6 months ago

Lucid Diagnostics Holds Inaugural #CheckYourFoodTube Precancer Testing Event for Former NFL Players

American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test
PAVM

PR Newswire

6 months ago

American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test

PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements
PAVM

PR Newswire

6 months ago

PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements

Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress
PAVM

PR Newswire

6 months ago

Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress

Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health
PAVM

PR Newswire

7 months ago

Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health

Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer
PAVM

PR Newswire

7 months ago

Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer

PAVmed Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
PAVM

Simply Wall St.

7 months ago

PAVmed Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

PAVM

Thomson Reuters StreetEvents

7 months ago

Q2 2024 PAVmed Inc Earnings Call

The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer
PAVM

PR Newswire

7 months ago

The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer

PAVmed Provides Business Update and Second Quarter 2024 Financial Results
PAVM

PR Newswire

7 months ago

PAVmed Provides Business Update and Second Quarter 2024 Financial Results

Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results
PAVM

PR Newswire

7 months ago

Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results

Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard® #CheckYourFoodTube Precancer Testing Event
PAVM

PR Newswire

8 months ago

Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard® #CheckYourFoodTube Precancer Testing Event

Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing
PAVM

PR Newswire

8 months ago

Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing

Lucid Diagnostics to Participate in Upcoming Investor Conferences
PAVM

PR Newswire

8 months ago

Lucid Diagnostics to Participate in Upcoming Investor Conferences

PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024
PAVM

PR Newswire

8 months ago

PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024
PAVM

PR Newswire

8 months ago

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024

Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume
PAVM

PR Newswire

8 months ago

Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume

Lucid Diagnostics Launches New Corporate Website
PAVM

PR Newswire

8 months ago

Lucid Diagnostics Launches New Corporate Website

Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
PAVM

PR Newswire

9 months ago

Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population

PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
PAVM

PR Newswire

9 months ago

PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing
PAVM

PR Newswire

9 months ago

4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing

Italian energy company targets Britain for fleet of 20 mini-nukes
PAVM

The Telegraph

9 months ago

Italian energy company targets Britain for fleet of 20 mini-nukes

It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend
PAVM

Simply Wall St.

9 months ago

It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend

Is Now The Time To Put Planet Fitness (NYSE:PLNT) On Your Watchlist?
PAVM

Simply Wall St.

9 months ago

Is Now The Time To Put Planet Fitness (NYSE:PLNT) On Your Watchlist?

Don't Buy Banc of California, Inc. (NYSE:BANC) For Its Next Dividend Without Doing These Checks
PAVM

Simply Wall St.

9 months ago

Don't Buy Banc of California, Inc. (NYSE:BANC) For Its Next Dividend Without Doing These Checks

4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow
PAVM

Motley Fool

9 months ago

4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow

Should You Be Adding Mueller Water Products (NYSE:MWA) To Your Watchlist Today?
PAVM

Simply Wall St.

9 months ago

Should You Be Adding Mueller Water Products (NYSE:MWA) To Your Watchlist Today?

Graham Full Year 2024 Earnings: EPS: US$0.42 (vs US$0.035 in FY 2023)
PAVM

Simply Wall St.

9 months ago

Graham Full Year 2024 Earnings: EPS: US$0.42 (vs US$0.035 in FY 2023)

Seoul resumes loudspeaker propaganda against North
PAVM

AFP

9 months ago

Seoul resumes loudspeaker propaganda against North

Lotto 6/49 - $64 million up for grabs in the next draw!
PAVM

CNW Group

10 months ago

Lotto 6/49 - $64 million up for grabs in the next draw!

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture
PAVM

Simply Wall St.

10 months ago

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Seoul says it will resume loudspeaker propaganda against North
PAVM

AFP

10 months ago

Seoul says it will resume loudspeaker propaganda against North

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend
PAVM

Simply Wall St.

10 months ago

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m
PAVM

Simply Wall St.

10 months ago

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week
PAVM

Barrons.com

10 months ago

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend
PAVM

Simply Wall St.

10 months ago

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued
PAVM

Simply Wall St.

10 months ago

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

PAVM

GuruFocus.com

10 months ago

PAVmed Inc (PAVM) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and Financial ...

PAVM

Thomson Reuters StreetEvents

10 months ago

Q1 2024 PAVmed Inc Earnings Call

PAVmed Provides Business Update and First Quarter 2024 Financial Results
PAVM

PR Newswire

10 months ago

PAVmed Provides Business Update and First Quarter 2024 Financial Results

Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results
PAVM

PR Newswire

10 months ago

Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results

Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall
PAVM

PR Newswire

a year ago

Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall

Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors
PAVM

PR Newswire

a year ago

Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors

PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024
PAVM

PR Newswire

a year ago

PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024
PAVM

PR Newswire

a year ago

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing
PAVM

PR Newswire

a year ago

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing

Veris teams up with Ohio University for cancer digital health pilot
PAVM

Medical Device Network

a year ago

Veris teams up with Ohio University for cancer digital health pilot

PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
PAVM

PR Newswire

a year ago

PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month
PAVM

PR Newswire

a year ago

Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month

Why PAVmed Inc. (PAVM) Dipped More Than Broader Market Today
PAVM

Zacks

a year ago

Why PAVmed Inc. (PAVM) Dipped More Than Broader Market Today

Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
PAVM

PR Newswire

a year ago

Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

PAVmed Inc. (NASDAQ:PAVM) Q4 2023 Earnings Call Transcript
PAVM

Insider Monkey

a year ago

PAVmed Inc. (NASDAQ:PAVM) Q4 2023 Earnings Call Transcript

PAVM

Thomson Reuters StreetEvents

a year ago

Q4 2023 PAVmed Inc Earnings Call

PAVmed Full Year 2023 Earnings: EPS Beats Expectations
PAVM

Simply Wall St.

a year ago

PAVmed Full Year 2023 Earnings: EPS Beats Expectations

PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results
PAVM

PR Newswire

a year ago

PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results

Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
PAVM

PR Newswire

a year ago

Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population

PAVmed Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX
PAVM

PR Newswire

a year ago

PAVmed Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX

Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference
PAVM

PR Newswire

a year ago

Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference

PAVmed to Hold a Business Update Conference Call and Webcast on March 27, 2024
PAVM

PR Newswire

a year ago

PAVmed to Hold a Business Update Conference Call and Webcast on March 27, 2024

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024
PAVM

PR Newswire

a year ago

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024

PAVmed Inc.'s (NASDAQ:PAVM) Intrinsic Value Is Potentially 66% Above Its Share Price
PAVM

Simply Wall St.

a year ago

PAVmed Inc.'s (NASDAQ:PAVM) Intrinsic Value Is Potentially 66% Above Its Share Price

Lucid Diagnostics Provides Update Regarding World Trade Center Health Program
PAVM

PR Newswire

a year ago

Lucid Diagnostics Provides Update Regarding World Trade Center Health Program

Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony
PAVM

PR Newswire

a year ago

Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony

Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors
PAVM

PR Newswire

a year ago

Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors

PAVM

GlobeNewswire

a year ago

Simplicity Group Unveils WeDYOR: Transforming Due Diligence for Crypto Investments

Share on Social Networks: